An Exploration of Trifluridine/Tipiracil Monotherapy and in Combination With Bevacizumab or Immune Checkpoint Inhibitors for Patients With Metastatic Colorectal Cancer: A Real-World Study
IF 4.3 3区 材料科学Q1 ENGINEERING, ELECTRICAL & ELECTRONIC
Caiyun Nie , Weifeng Xu , Beibei Chen , Huifang Lv , Jianzheng Wang , Yingjun Liu , Yunduan He , Saiqi Wang , Jing Zhao , Xiaobing Chen
{"title":"An Exploration of Trifluridine/Tipiracil Monotherapy and in Combination With Bevacizumab or Immune Checkpoint Inhibitors for Patients With Metastatic Colorectal Cancer: A Real-World Study","authors":"Caiyun Nie , Weifeng Xu , Beibei Chen , Huifang Lv , Jianzheng Wang , Yingjun Liu , Yunduan He , Saiqi Wang , Jing Zhao , Xiaobing Chen","doi":"10.1016/j.clcc.2022.11.005","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p><span><span>Trifluridine/tipiracil (TAS-102) has achieved modest efficacy in the late-line treatment of </span>metastatic colorectal cancer. The present study aimed to explore the clinical efficacy and </span>drug toxicities of TAS-102 for patients with metastatic colorectal cancer in real-world clinical setting.</p></div><div><h3>Methods</h3><p><span><span>From October 2020 to February 2022, patients with metastatic colorectal cancer who failed from 2 or more lines of prior therapy and treated with TAS-102 monotherapy, in combination with </span>bevacizumab<span> or immune checkpoint inhibitors (ICIs) were analyzed. The evaluation indicators were </span></span>progression free survival (PFS), objective response rate , disease control rate (DCR), overall survival (OS) and drug toxicities.</p></div><div><h3>Results</h3><p>A total of 70 patients were enrolled. The objective response rate and DCR were 1.4% and 68.6%. The median PFS and OS were 6.0 (95% CI: 4.1-7.9) and 10.0 (95% CI: 8.3-11.7) months. Compared with TAS-102 monotherapy and TAS-102 plus ICIs, TAS-102 plus bevacizumab obtained superior DCR (75.9% vs. 50% vs. 40%, <em>P</em> = .047), PFS (6.3m vs. 3.0 m vs. 3.0 m, <em>P</em> = .041) and OS (12.0 m vs. 6.5 m vs. 6.0m, <em>P</em><span><span> = .013). Patients without prior regorafenib or </span>fruquintinib therapy obtained better median PFS (6.3 vs. 4.3 m, </span><em>P</em> = .031) and OS (NR vs. 9.0 m, <em>P</em><span><span> = .036). Other indicators, including age, tumor site, KRAS status and use of fluoropyrimidine as last regimen before TAS-102, did not affect the clinical efficacy of TAS-102. The most frequent adverse events were </span>leukopenia, neutropenia, anemia, fatigue, nausea, and vomiting.</span></p></div><div><h3>Conclusion</h3><p>In real-world clinical setting, TAS-102 showed consistent clinical efficacy and manageable safety with previous prospective clinical studies. Compared with monotherapy and TAS-102 plus ICIs, TAS-102 plus bevacizumab demonstrated better clinical efficacy for metastatic colorectal cancer.</p></div>","PeriodicalId":3,"journal":{"name":"ACS Applied Electronic Materials","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Electronic Materials","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1533002822001311","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, ELECTRICAL & ELECTRONIC","Score":null,"Total":0}
引用次数: 1
Abstract
Background
Trifluridine/tipiracil (TAS-102) has achieved modest efficacy in the late-line treatment of metastatic colorectal cancer. The present study aimed to explore the clinical efficacy and drug toxicities of TAS-102 for patients with metastatic colorectal cancer in real-world clinical setting.
Methods
From October 2020 to February 2022, patients with metastatic colorectal cancer who failed from 2 or more lines of prior therapy and treated with TAS-102 monotherapy, in combination with bevacizumab or immune checkpoint inhibitors (ICIs) were analyzed. The evaluation indicators were progression free survival (PFS), objective response rate , disease control rate (DCR), overall survival (OS) and drug toxicities.
Results
A total of 70 patients were enrolled. The objective response rate and DCR were 1.4% and 68.6%. The median PFS and OS were 6.0 (95% CI: 4.1-7.9) and 10.0 (95% CI: 8.3-11.7) months. Compared with TAS-102 monotherapy and TAS-102 plus ICIs, TAS-102 plus bevacizumab obtained superior DCR (75.9% vs. 50% vs. 40%, P = .047), PFS (6.3m vs. 3.0 m vs. 3.0 m, P = .041) and OS (12.0 m vs. 6.5 m vs. 6.0m, P = .013). Patients without prior regorafenib or fruquintinib therapy obtained better median PFS (6.3 vs. 4.3 m, P = .031) and OS (NR vs. 9.0 m, P = .036). Other indicators, including age, tumor site, KRAS status and use of fluoropyrimidine as last regimen before TAS-102, did not affect the clinical efficacy of TAS-102. The most frequent adverse events were leukopenia, neutropenia, anemia, fatigue, nausea, and vomiting.
Conclusion
In real-world clinical setting, TAS-102 showed consistent clinical efficacy and manageable safety with previous prospective clinical studies. Compared with monotherapy and TAS-102 plus ICIs, TAS-102 plus bevacizumab demonstrated better clinical efficacy for metastatic colorectal cancer.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
